Orion Porfolio Solutions LLC Cuts Stock Position in Amgen Inc. $AMGN

Orion Porfolio Solutions LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 29,462 shares of the medical research company’s stock after selling 1,488 shares during the period. Orion Porfolio Solutions LLC’s holdings in Amgen were worth $8,314,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company’s stock worth $15,204,047,000 after purchasing an additional 165,281 shares during the period. State Street Corp boosted its stake in shares of Amgen by 0.6% in the 2nd quarter. State Street Corp now owns 29,357,026 shares of the medical research company’s stock valued at $8,196,775,000 after buying an additional 177,035 shares during the period. Geode Capital Management LLC grew its position in shares of Amgen by 2.3% during the second quarter. Geode Capital Management LLC now owns 13,018,617 shares of the medical research company’s stock worth $3,619,489,000 after buying an additional 291,271 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Amgen by 5.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock worth $3,600,043,000 after buying an additional 687,735 shares during the period. Finally, Laurel Wealth Advisors LLC increased its stake in shares of Amgen by 27,765.8% during the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock worth $1,870,880,000 after buying an additional 6,676,575 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the subject of several analyst reports. Morgan Stanley boosted their price target on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Truist Financial lifted their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Piper Sandler boosted their target price on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Barclays assumed coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price on the stock. Finally, Sanford C. Bernstein cut Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $354.17.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Price Performance

Shares of NASDAQ AMGN opened at $369.53 on Friday. The stock has a fifty day moving average price of $353.26 and a 200 day moving average price of $322.43. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market cap of $199.20 billion, a PE ratio of 25.97, a P/E/G ratio of 3.65 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.